Clinical Trials Directory

Trials / Unknown

UnknownNCT05141422

A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers

A Single-centre, Single-arm, Open-label and Fixed-sequence Drug-drug Interaction Study to Evaluate the Effect of Efavirenz on the Pharmacokinetics of SHR2150 in Healthy Chinese Subjects

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Jiangsu HengRui Medicine Co., Ltd. · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The study is a single-centre, open-label, fixed-sequence, self-controlled clinical trial. It is planned to enroll 20 healthy adult subjects. Subjects will take SHR2150 on Day 1 and Day 21, and take efavirenz from Day 7 to Day 26.

Conditions

Interventions

TypeNameDescription
DRUGSHR2150 tablet、efavirenzSHR2150 tablet single dose, Efavirenz single dose.

Timeline

Start date
2021-12-13
Primary completion
2022-01-15
Completion
2022-01-22
First posted
2021-12-02
Last updated
2021-12-20

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05141422. Inclusion in this directory is not an endorsement.